Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation

A Practical Guide for Neurologists

Isabella Canavero, Giuseppe Micieli, Maurizio Paciaroni

Research output: Contribution to journalArticle

Abstract

Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.

Original languageEnglish
Pages (from-to)396-404
Number of pages9
JournalClinical and Applied Thrombosis/Hemostasis
Volume24
Issue number3
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Anticoagulants
Atrial Fibrillation
Stroke
Food-Drug Interactions
Vitamin K
Intracranial Hemorrhages
Acute Coronary Syndrome
Drug Interactions
Practice Guidelines
Neurologists
Guidelines
Therapeutics

Keywords

  • direct oral anticoagulant
  • nonvalvular atrial fibrillation
  • stroke

ASJC Scopus subject areas

  • Hematology

Cite this

@article{e8f39e1922094e34a68b36446cad0579,
title = "Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists",
abstract = "Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.",
keywords = "direct oral anticoagulant, nonvalvular atrial fibrillation, stroke",
author = "Isabella Canavero and Giuseppe Micieli and Maurizio Paciaroni",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/1076029617720068",
language = "English",
volume = "24",
pages = "396--404",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation

T2 - A Practical Guide for Neurologists

AU - Canavero, Isabella

AU - Micieli, Giuseppe

AU - Paciaroni, Maurizio

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.

AB - Direct oral anticoagulants (DOACs) are valid alternative options to vitamin K antagonists due to their limited interactions with drugs or food and the fact that they do not require regular coagulation monitoring. To this regard, recent practice guidelines recommend that DOACs should be considered as first-line anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). This review (1) outlines current international guidelines for the management of DOACs to prevent stroke in patients with NVAF, (2) outlines indications for elderly patients as well as specific settings including acute coronary syndromes and intracranial hemorrhage, and (3) offers a practical guide for the use of DOACs in neurological settings.

KW - direct oral anticoagulant

KW - nonvalvular atrial fibrillation

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85042066354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042066354&partnerID=8YFLogxK

U2 - 10.1177/1076029617720068

DO - 10.1177/1076029617720068

M3 - Article

VL - 24

SP - 396

EP - 404

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 3

ER -